AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced during the Phacilitate Cell & Gene Therapy Forum new data showing that one treatment of its lead product Glybera(R) results in a long term significant and clinically important lowering of the incidence of acute pancreatitis in Lipoprotein Lipase Deficient patients.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on February 2nd, 2009